MedTrace Logo

OMO-1 in Solid Malignancies

NCT03138083 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-06-11

No results posted yet for this study

Summary

This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.

Conditions

  • Neoplasms

Interventions

DRUG

OMO-1

OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase

Sponsors & Collaborators

  • Octimet Oncology N.V.

    lead INDUSTRY

Principal Investigators

  • Martijn Lolkema, MD, PhD · Erasmus Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-08
Primary Completion
2020-05-25
Completion
2020-05-25
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138083 on ClinicalTrials.gov